DE60325347D1 - Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen - Google Patents

Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen

Info

Publication number
DE60325347D1
DE60325347D1 DE60325347T DE60325347T DE60325347D1 DE 60325347 D1 DE60325347 D1 DE 60325347D1 DE 60325347 T DE60325347 T DE 60325347T DE 60325347 T DE60325347 T DE 60325347T DE 60325347 D1 DE60325347 D1 DE 60325347D1
Authority
DE
Germany
Prior art keywords
derivatives
sub
substituted
acids
chinoloncarboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325347T
Other languages
German (de)
English (en)
Inventor
Timothy B C Johnstone
Derk J Hogenkamp
Kelvin W Gee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE60325347D1 publication Critical patent/DE60325347D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DE60325347T 2002-05-14 2003-05-12 Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen Expired - Lifetime DE60325347D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (1)

Publication Number Publication Date
DE60325347D1 true DE60325347D1 (de) 2009-01-29

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325347T Expired - Lifetime DE60325347D1 (de) 2002-05-14 2003-05-12 Substituierte chinoloncarbonsäuren, ihre derivate, wirkungsort und anwendungen

Country Status (16)

Country Link
US (2) US7355047B2 (enExample)
EP (1) EP1503759B1 (enExample)
JP (1) JP4532263B2 (enExample)
KR (1) KR20040107525A (enExample)
CN (1) CN1652784A (enExample)
AT (1) ATE417613T1 (enExample)
AU (1) AU2003229043B2 (enExample)
BR (1) BR0309965A (enExample)
CA (1) CA2484308A1 (enExample)
DE (1) DE60325347D1 (enExample)
DK (1) DK1503759T3 (enExample)
ES (1) ES2319176T3 (enExample)
IL (1) IL164734A0 (enExample)
MX (1) MXPA04011156A (enExample)
NZ (1) NZ536061A (enExample)
WO (1) WO2003097564A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484308A1 (en) * 2002-05-14 2003-11-27 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
UA85711C2 (ru) * 2004-05-06 2009-02-25 Зе Регентс Оф Зе Юниверсити Оф Калифорния Замещенные енаминоны, их производные и их применение
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
MX2007012335A (es) * 2005-04-11 2007-11-21 Hoffmann La Roche (3,4-dihidro-quinazolina-2-il)-indano-1-il-aminas.
MX2007013606A (es) * 2005-05-04 2007-12-10 Hoffmann La Roche (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
ATE475650T1 (de) * 2005-12-05 2010-08-15 Merck Sharp & Dohme Positive allosterische chinolon-m1- rezeptormodulatoren
CN101374849A (zh) * 2005-12-24 2009-02-25 沃泰克斯药物股份有限公司 作为abc转运蛋白调控剂的喹啉-4-酮衍生物
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2007106537A2 (en) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
KR20090035744A (ko) * 2006-08-10 2009-04-10 페레르 인터내쇼날 에스.에이. Ｇａｂａ 수용체의 친화력을 갖는 1ｈ-퀴놀린-4-원 화합물,제조방법, 사용방법 및 조성물
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
ES2399071T3 (es) 2006-10-16 2013-03-25 Bionomics Limited Nuevos compuestos ansiolíticos
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2009307892A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic M1 receptor positive allosteric modulators
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (enExample) * 1974-06-11 1982-04-01
US4390541A (en) 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
WO2000068202A1 (en) 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
CA2484308A1 (en) * 2002-05-14 2003-11-27 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Also Published As

Publication number Publication date
EP1503759A4 (en) 2006-02-15
AU2003229043A1 (en) 2003-12-02
WO2003097564A3 (en) 2004-02-26
US20060178516A1 (en) 2006-08-10
ES2319176T3 (es) 2009-05-05
BR0309965A (pt) 2005-03-01
US7355047B2 (en) 2008-04-08
WO2003097564A2 (en) 2003-11-27
IL164734A0 (en) 2005-12-18
JP2005535592A (ja) 2005-11-24
CN1652784A (zh) 2005-08-10
JP4532263B2 (ja) 2010-08-25
NZ536061A (en) 2008-09-26
ATE417613T1 (de) 2009-01-15
HK1072905A1 (en) 2005-09-16
EP1503759A2 (en) 2005-02-09
EP1503759B1 (en) 2008-12-17
US20080176897A1 (en) 2008-07-24
MXPA04011156A (es) 2005-02-17
CA2484308A1 (en) 2003-11-27
KR20040107525A (ko) 2004-12-20
AU2003229043B2 (en) 2008-12-04
DK1503759T3 (da) 2009-04-14

Similar Documents

Publication Publication Date Title
EP1503759A4 (en) SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS, DERIVATIVES THEREOF, SITE OF ACTION AND USES THEREOF
EP1391201A4 (en) MEDICAL COMPOSITIONS
DE60215652D1 (de) Aromatische hydroxamsäurederivate, die sich als hdac inhibitoren eignen
DE602005013417D1 (de) (biphenyl)carbonsäuren und derivate davon
DK2298743T3 (da) p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
IS6348A (is) (1a,3a,5a)(3-amínómetýl bísýkló[3.2.0]hept-3-ýl)-ediksýra, lyfjasamsetningar og notkun efnasambandsins til framleiðslu á lyfjum
EP2234963A4 (en) LEVODOPA FORMULATIONS WITH CONTROLLED RELEASE AND ITS USE
DK1685105T3 (da) Allosteriske modulatorer af metabotropiske glutamatreceptorer
WO2006034418A3 (en) Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
NO20055370D0 (no) Alfa-substituert karboksylsyre som PPAR modulatorer
NO20072767L (no) Gabapentin prodrug vedvarende frigivelse orale doseringsformer
EP1314712A4 (en) NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
DK1429807T3 (da) Kombination af et NSAID og en PDE4-inhibitor
CY1111858T1 (el) Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων
DK0966424T3 (da) Aminobenzophenoner som inhibitorer for interleukin og TNF
NO20056161L (no) Formuleringer for behandling av artrittilstander
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
DE50305117D1 (de) Essig- und propionsäureamide
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
UA85711C2 (ru) Замещенные енаминоны, их производные и их применение
ATE498600T1 (de) Inden derivate als pharmazeutika
DE602006014185D1 (de) 3-arylisoxazol-4-carbonylbenzofuranderivative
ATE402153T1 (de) Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE60216083D1 (de) (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE
DK1212321T3 (da) Mellemprodukter til fremstilling af quinolone carboxylsyrederivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition